POSA148 Cost Effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

[1]  C. Cameron,et al.  Efficacy classification of modern therapies in multiple sclerosis. , 2021, Journal of comparative effectiveness research.

[2]  Jeffrey A. Cohen,et al.  Ofatumumab versus Teriflunomide in Multiple Sclerosis. , 2020, The New England journal of medicine.

[3]  D. Feeny,et al.  Age- and sex-specific Canadian utility norms, based on the 2013–2014 Canadian Community Health Survey , 2018, Canadian Medical Association Journal.

[4]  N. Joshi,et al.  Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  J. Mauskopf,et al.  Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States , 2016, Journal of medical economics.

[6]  Martin Duddy,et al.  UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model , 2014, BMJ Open.

[7]  Pablo Villoslada,et al.  Multiple Sclerosis Susceptibility Genes: Associations with Relapse Severity and Recovery , 2013, PloS one.

[8]  Kelvin K. W. Chan,et al.  Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Christopher McCabe,et al.  Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  G. Samsa,et al.  Cost of multiple sclerosis by level of disability: a review of literature , 2005, Multiple sclerosis.

[11]  Amit Bar-Or,et al.  Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  G. Torrance,et al.  Cost and health related quality of life consequences of multiple sclerosis , 2000, Multiple sclerosis.

[13]  P. Pocklington,et al.  Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980. , 1982, Acta neurologica Scandinavica.

[14]  P. Lefebvre,et al.  Perspectives on the Common Drug Review Process at the Canadian Agency for Drugs and Technologies in Health , 2017 .

[15]  A. Gustavsson,et al.  Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. , 2012, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.

[16]  R. Nixon,et al.  The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  R. Pokorski.  Long-term survival experience of patients with multiple sclerosis. , 1997, Journal of insurance medicine.